Julie Krop

This profile gathers the share dealings of Julie Krop across 2 companies, led by AMAG Pharmaceuticals Inc. and Aquestive Therapeutics, Inc. In total, 25 filings cover trades dated from 1 June 2015 to 23 June 2026.

Both buying and selling appear: 1 purchase worth €89k, against 4 sales worth €351k. Taken together, the sales exceed the purchases by €263k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 19 share grants and 1 option exercise. So far in 2026, the count stands at no purchases and 1 sale.

Most recently, on 24 June 2026, the filings show an open-market sale worth €110k in Aquestive Therapeutics, Inc. The last purchase on record was published on 29 May 2019, which is 2,704 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.